All In Biotech

Drug Trial Radar · NCT02680574

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Phase 3, Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD) (PRO2TECT-CONVERSION)

Last checked: Nov 20, 2026Latest source record: Jun 27, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,725 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,725

Actual

Start

Feb 2016

Primary completion

Jun 18, 2020

Study completion Jul 31, 2020

Sponsor

Lead sponsor
Akebia TherapeuticsIndustry
Sponsor type
Industry
First posted
Feb 11, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multicenter, randomized, open-label, active-controlled Phase 3 study for the maintenance treatment of anemia in participants with Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Conditions

  • Anemia
  • Non-Dialysis-Dependent Chronic Kidney Disease

Interventions

  • VadadustatDrug

    Oral dose administered once daily for ≥36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.

  • Darbepoetin alfaDrug

    Subcutaneous or intravenous dose administered for ≥36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis. For participants already on Darbepoetin alfa, the initial dosing regimen in the study was based on the prior dosing regimen.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36)Time frame: Baseline; Weeks 24 to 36
  2. Median Time to First Major Adverse Cardiovascular Event (MACE)Time frame: Up to Week 208

Locations

503 sites in 30 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Huntsville, Alabama

  • Research Site

    Tuscumbia, Alabama

  • Research Site

    Glendale, Arizona

  • Research Site

    Mesa, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Anaheim, California

  • Research Site

    Bakersfield, California

  • Research Site #1

    Chula Vista, California

  • Research Site #2

    Chula Vista, California

  • Research Site

    El Centro, California

  • Research Site

    Fountain Valley, California

  • Research Site

    Glendale, California

  • Research Site

    Granada Hills, California

  • Research Site

    La Mesa, California

  • Research Site

    Laguna Hills, California

  • Research Site

    Long Beach, California

  • Research Site

    Long Beach, California

  • Research Site

    Los Angeles, California

  • Research Site

    Lynwood, California

  • Research Site #1

    Northridge, California

  • Research Site #2

    Northridge, California

  • Research Site

    Riverside, California

  • Research Site

    Roseville, California

  • Research Site

    Salinas, California

  • Research Site

    San Diego, California

  • Research Site #1

    San Dimas, California

  • Research Site #2

    San Dimas, California

  • Research Site

    Santa Ana, California

  • Research Site

    Santa Monica, California

  • Research Site

    Sherman Oaks, California

  • Research Site

    Thousand Oaks, California

  • Research Site

    Whittier, California

  • Research Site

    Whittier, California

  • Research Site

    Arvada, Colorado

  • Research Site

    Denver, Colorado

  • Research Site

    Westminster, Colorado

  • Research Site

    Stamford, Connecticut

Showing 40 of 503 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.